Stability of Blood Eosinophils in COPD with Multiple Acute Exacerbations Within 1 Year and Its Relationship with Prognosis

Figures & data

Table 1 Characteristics of Patients

	Non-EOS Group (n=108)	Fluctuating Group (n=46)	EOS Group (n=48)	P-value
Male, n (%)	86(79.6)	42(91.3)	42(87.5)	0.148
Age (years)	76.5±8.8	77.3±9.8	76.5±8.8	0.585
Comorbidities
Heart failure, n (%)	54(50)	21(45.7)	21(43.8)	0.739
Coronary heart disease, n (%)	32(29.6)	14(30.4)	18(37.5)	0.608
Type 2 diabetes, n (%)	10(9.3)	5(10.8)	13(27.1)^a	0.010
Cerebrovascular disease, n (%)	40(37)	15(32.6)	18(37.5)	0.850
mMRC≥2, (n,%)	98(90.7)	43(93.5)	44(91.7)	0.855
History of hospital admission in the previous year, (n, %)	48(44)	19(41.3)	18(37.5)	0.715
Course of disease (year)	10(8–20)	10(8–12.8)	10(5.3–20)	0.735
Inhaled medications
LAMA or LABA+LAMA	9(8.3)	3(6.5)	5(10.4)	0.793
ICS+LABA	59(54.6)	18(39.1)	26(54.2)	0.187
ICS+LABA+LAMA	9(8.3)	3(6.5)	4(8.3)	0.923

Note: ^aCompared to non-EOS group, P=0.04<0.05.

Table 2 Mortality and Readmission Rates in Each Group

	Non-EOS Group (n=108)	Fluctuating Group (n=46)	EOS Group (n=48)	P-value
Death, (n,%)	25 (23.1)	5 (10.8)	4^a (8.3)	0.035
Readmission, (n,%)	38(35.2)^b	26(56.5)	15(31.3)^c	0.037

Notes: ^aCompared to the non-EOS group, P =0.02 (RR:2.387 95% CI 1.1–5.18); COX regression analysis: compared to non-EOS group, adjusted HR =0.323, 95% CI 0.113–0.930, P =0.036; ^bCompared to the fluctuating group, P =0.032; COX regression analysis: compared to the fluctuating group, adjusted HR=0.575, 95% CI 0.347–0.954, P =0.032; ^cCompared to the fluctuating group, P =0.021; COX regression analysis: compared to the fluctuating group, adjusted HR =0.486, 95% CI 0.256–0.923, P =0.027.